Therefore, VEGFR-2-derived peptide vaccines are potent options for the treatment of melanoma since they target both tumor cells and endothelial cells while producing substantial anti-tumor immune responses with low toxicity (Mahabeleshwar and Byzova 2007; Zahedipour et al. 2021). The gene discussed is KDR; the disease is melanoma.